ViaNautis Bio Ltd
- | Biotech or pharma, therapeutic R&D
ViaNautis Bio develops genetic medicines for CNS diseases, including epilepsy, Frontotemporal Dementia (FTD), and Parkinson’s, using proprietary PolyNaut® nanovesicles (PNVs). PNVs enable efficient delivery of DNA, ASO, and mRNA to the brain with high specificity, leveraging ligand-based targeting. We have demonstrated BBB crossing with angiopep2 PNVs, effectively targeting neurons and astrocytes while avoiding microglia. Compared to AAV and LNPs, PNVs offer re-dosing potential, 4°C stability, scalability, and large cargo capacity. ViaNautis is backed by leading investors, including 4BIO, BGF, UCBV, Lilly Ventures, and CFF, and has entered a multi-year, multi-target partnership with Eli Lilly to advance novel genetic medicines.
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}